PSYENCE BIOMEDICAL LTD.
PBM, PBMWW · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D46Clinical-stage psychedelic biopharma with no revenue and ongoing losses; flattering ROE/ROA are fair-value accounting artifacts, not real returns.
Strengths
- ~6.6 quarters cash runway (~50th pct) and ~$6.1M cash
- Advancing Phase IIb psilocybin program with vertically integrated PsyLabs investment
Risks
- No product revenue; FY net loss $6.9M (prior-year 'profit' was warrant/debt fair-value gains)
- Reported ROE 15%/ROA 14% are non-operating artifacts, not operating returns
- Binary clinical and ongoing funding/dilution risk typical of pre-revenue biotech
Notable findings
- Cash burnNegative free cash flow (-3.7M)
- Notable holderHeld by 1 notable fund(s): GOLDMAN SACHS GROUP INC (as of 2026-03-31)
Key metrics
Return on equity
15.1%
Return on assets
13.8%
Free cash flow
-$4M
Tangible book value
$7M
Cash & investments
$6M
Cash runway
7q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-06-22 | 2026-03-31 | 0001213900-26-070607 ↗ |
| 20-F | 2025-06-25 | 2025-03-31 | 0001213900-25-057893 ↗ |
| 20-F | 2024-07-29 | 2024-03-31 | 0001410578-24-001112 ↗ |
| 20-F | 2024-01-31 | 2024-01-25 | 0001104659-24-008872 ↗ |